Non-Hodgkin lymphoma Posts Page 2 on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Evaluating RBD chemotherapy for recurrent or non-responsive non-Hodgkin lymphoma

Posted by on Jun 21, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...

Read More

Evaluating rituximab plus lenalidomide for first-line treatment of follicular lymphoma

Posted by on Jun 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) alone or with lenalidomide (Revlimid) for the first-line treatment of follicular lymphoma (FL). This study concluded that rituximab plus lenalidomide was effective and well-tolerated in these patients. Some background Immunochemotherapy is the current standard...

Read More

Evaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma

Posted by on Jun 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...

Read More

Looking for young patients with non-Hodgkin’s lymphoma to test a treatment combination

Posted by on Jun 14, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 3 trial is comparing the effectiveness of ibrutinib (Imbruvica) plus chemotherapy versus chemotherapy alone in children and young adults with B-cell non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be survival without cancer returning, growing or spreading. The details Ibrutinib is a targeted therapy...

Read More

Evaluating polatuzumab vedotin with chemoimmunotherapy for diffuse large B-cell lymphoma

Posted by on Jun 5, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of polatuzumab vedotin (Pola) combined with chemoimmunotherapy for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that combining Pola with these regimens was promising, with manageable side effects. Some background DLBCL is one of the most common types...

Read More

Evaluating chemoimmunotherapy for children with aggressive B-cell lymphoma

Posted by on May 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of chemoimmunotherapy in children and adolescents with aggressive B-cell non-Hodgkin’s lymphoma (NHL). This study concluded that combined chemoimmunotherapy is highly effective in these young patients. Some background B-cell NHL is one of the most common types of lymphoma in children and...

Read More

Evaluating the FMT regimen before a stem cell transplant in patients with aggressive non-Hodgkin lymphoma

Posted by on May 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of the FMT (fludarabine, melphalan, total body irradiation) regimen in patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that this regimen was well-tolerated and effective. Some background Many patients with aggressive NHL...

Read More

Searching for participants to try a new combination of targeted therapy for relapsed or non-responsive B-cell lymphomas.

Posted by on May 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is investigating the effectiveness of a new combination of treatments, nivolumab (Opdivo) and varlilumab (CDX-1127), for non-responsive, aggressive B-cell lymphomas. The main outcome that will be measured is the proportion of patients that respond to treatment (overall response rate). This trial is recruiting in the US. The...

Read More

Searching for patients with lymphoma or leukemia to test T-cell therapy after stem cell transplantation

Posted by on May 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating how well CD8+ memory T-cell therapy works in patients with leukemia or lymphoma after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have full chimerism (donor cells work completely and only donor cells can be identified after transplant) after therapy. This...

Read More

Evaluating polatuzumab vedotin and pinatuzumab vedotin for relapsed or refractory NHL

Posted by on May 20, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) combined with either polatuzumab vedotin (pola) or pinatuzumab vedotin (pina) for patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that pola was associated with better...

Read More